Skip to main content

UnitedHealth Group Rockets To New High

Friday, April 16, 2021 | Thomas Hughes
UnitedHealth Group Rockets To New High

Tailwinds Support UnitedHealth Group

Let's face it, the healthcare industry is growing and supported by government policy and that's why UnitedHealth Group (NYSE: UNH) is moving higher. That and the fact results are topping the analyst's estimates, the company keeps guiding the market higher, and the outlook for dividend growth is very positive. In our view, if you are looking for blue-chip quality dividend growth stock you could do far worse than UnitedHealth and for more reasons than one. UnitedHealth, as an insurer and services provider, is at the nexus where providers meet patients and well-positioned to make money from both. 

UnitedHealth Group Beats And Raises Guidance, Again

As often as UnitedHealth beats the consensus and raises guidance we're beginning to sound like a broken record. Cliche's aside, UnitedHealth had not only a great quarter but one in which it beat its own guidance. The guidance they themselves raised following the last reporting period. The $70.2 billion in revenue is up sequentially by 7.6% and annually by 9.0% topping the analysis consensus by 160 bps YOY. The gains are driven by a solid improvement in both operating segments as well. The core UnitedHealthcare saw its revenue rise by 7.9% while the Optum healthcare services group grew 10.8%. The gain in both segments was driven by an increase in clients that, when coupled with lower healthcare claims, resulted in health bottom-line results as well. 

Moving down the report the company delivered a 90 basis point improvement in margins. The companies operating cost ratio came in at 14.6% of revenue versus the previous 15.5% to produce a beat in terms of GAAP and adjusted earnings. At the operating level, cash flow increased by 104% from last year driving GAAP EPS up by 35% and adjusted by a similar amount. The GAAP $5.08 beat by $0.88 while the adjusted $5.31 beat by $0.92 to improve what was an already very bullish outlook for dividends and dividend growth. 

Looking forward, the company is expecting its adjusted earnings in the range of $18.10 to $18.60 versus the $18.20 consensus held by the analysts. This is better than the previous guidance but still too cautious in light of 1) the company's 100% record of beating consensus and 2) the strength of healthcare trends in the U.S, and that doesn't include any boost healthcare may see when the reopening gets into full swing. There's a lot of pent-up demand for services and UnitedHealth Group is ready to facilitate them. 

You Can Expect A UnitedHealth Group Dividend Increase Any Day 

UnitedHealth Group is a high-quality dividend growth stock and it is expected to issue the next increase with the next distribution. Based on the history, 11 years of consecutive increases, the declaration should come in the 2nd quarter and could be worth upwards of 20%. Not only does the history back up this assessment but so does the earnings and balance sheet. The company is only paying out 27% of its earnings with earnings on the rise, ample free cash flow, and only very light leverage. The yield is a bit low at 1.35% but there are the growth and dividend-growth to consider, factors we think more than make up the difference. 

The Technical Outlook: UnitedHealth Breaks Out To New High

Shares of UnitedHealth surged more than 4.0% on the Q1 news to break above resistance and set a new all-time high. Now, with the bulls in control, we see this stock moving up another $10 to $50 in the near term at least. The most recent analyst activity has the stock valued in the range of $430 to $450 which is in line with our assessment. Investors looking to get into this stock may want to begin with a small position and then pyramid into a larger holding when prices show weakness.

UnitedHealth Group Rockets To New High

Featured Article: Trading Options- What is a Strangle?


7 Stocks That Could Benefit From a Capital Gains Tax Hike

One thing every investor needs to learn is the effect of capital gains on their investments. Every time an investor sells a stock that has appreciated in value, that capital gain is subject to being taxed. Stocks that are held for less than a year pay a short-term capital gains tax rate. Stocks that are held for over a year pay a long-term capital gains tax rate.

In general, a capital gains tax hike is a bearish indicator for stocks. However, there are a couple of strategies that can help investors avoid some of the tax hit. One strategy is to keep your investments in an individual retirement account (IRA) or 401(k). However many higher-income earners want to have more access to the funds in their brokerage accounts.

A sound strategy for these investors involves buying dividend stocks. Dividend income is also taxed (unless it is reinvested), but typically when the capital gains tax rate is raised, the dividend income rate stays the same. This makes dividend stocks more attractive.

Investing in dividend stocks is never a bad idea, but at times when the capital gains tax rate is favorable, growth stocks provide a better reward for investor capital. But when long-term capital gains tax rates go up, those gains can get expensive.

In this special presentation, we’ll give you seven stocks that have a nice dividend yield and a strong story to go along with them.

View the "7 Stocks That Could Benefit From a Capital Gains Tax Hike".


Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
UnitedHealth Group (UNH)2.5$409.80+0.3%1.22%23.54Buy$412.26
Compare These Stocks  Add These Stocks to My Watchlist 

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.